Clinical trials located in

Stoke-on-Trent

Stoke-on-Trent city is located in United Kingdom. Currently, 8 clinical trials are being conducted in this city.

Stoke-on-Trent, located in the heart of England, is renowned for its rich industrial heritage, particularly in ceramics. Known as the World Capital of Ceramics, it has been home to iconic pottery brands like Wedgwood, Royal Doulton, and Spode. The city’s unique cultural landscape is dotted with museums and factories that celebrate its pottery legacy. Stoke-on-Trent also boasts the Trent and Mersey Canal, pivotal in the pottery industry’s growth by facilitating the transport of goods. Additionally, it hosts the annual British Ceramics Biennial, showcasing contemporary ceramic art.

  • CT-EU-00116351

    Comparing ruxolitinib, hydroxycarbamide, and Interferon as first-line treatments for high-risk Polycythemia Vera

    The study, known as MITHRIDATE, investigates the effectiveness of the drug Ruxolitinib compared to either Hydroxycarbamide or Interferon Alpha for patients with high-risk Polycythemia Vera, a type of blood disorder. This Phase III clinical trial aims to determine which treatment is more effective in managing the disease without leading to additional health complications.

    Patients in the trial are assigned to receive either Ruxolitinib or the best available therapy, chosen from Hydroxycarbamide or Interferon Alpha, as decided by the overseeing doctors. The course of the study involves regular monitoring and assessments to evaluate the impact of these treatments on the disease’s progression and patients’ overall health and quality of life. The study is conducted in a controlled environment to ensure reliable results.

    • Interferon-Alpha
    • Hydroxycarbamide
    • Ruxolitinib
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Comparing abelacimab and apixaban treatments for blood clots in cancer patients

    This research study is looking at how two different medicines, abelacimab and apixaban, can help people with a severe medical problem called Cancer Associated Thrombosis (CAT). CAT happens when blood clots form inside the veins (a condition called Venous Thromboembolism or VTE) in people with cancer. These blood clots can cause other serious health issues. In this study, the researchers will see if abelacimab (which is given monthly) is as good as apixaban if not better (which you take twice a day every day) for six months. And then look at whether the blood clots come back, if any bleeding happens, and if patients had to stop treatment.

    • Abelacimab
    • Apixaban
  • Examining new dosing of belantamab for resistant multiple myeloma

    The study is called DREAMM-14 and is intended for people with a disease called multiple myeloma that does not respond to other treatments. Scientists are investigating various possible uses of a drug called belantamab mafodotin. They want to see if changing the dose of the drug or the frequency of its administration can fight the disease more effectively and cause fewer side effects. They will also look at changes in your vision and the condition of the cornea (the clear front part of the eye) on a scale of 0 to 4. This scale assesses the condition of the cornea and any changes in vision, with 0 being no change and 4 being a major change. Doctors will measure how many people experience corneal changes, how long they last, and whether the events are related to the amount of medication they take. They will also look at how the disease responds to the medicine and how long it takes to take treatment.

    • Belantamab mafodotin
  • Comparatively studying drug combinations for multiple myeloma treatment

    This study is testing different combinations of drugs used to treat a cancer called multiple myeloma. Patients will receive one of two sets of treatments. One set contains a medicine called belantamab mafodotin combined with two others, while the second set contains the same two medicines but with another third medicine called bortezomib. The main goal is to determine which of these combinations is more effective in patients with multiple myeloma, especially those for whom other treatments have failed. Researchers will measure how many participants see the disease go away, how long the disease is kept in check, and overall survival rates. In addition, they will use questionnaires to assess your quality of life and understand the range of symptoms or problems you may experience during the examination.

    • Belantamab mafodotin
    • Pomalidomide
    • Dexamethasone
    • Bortezomib
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in United Kingdom:

.